10-Q: Tempest Therapeutics Faces Going Concern Amid Strategic Review

Tempest Therapeutics reports significant cash burn and a going concern warning, while advancing key oncology programs and exploring strategic alternatives.

Summary

• Reported a net loss of $3.5 million for the three months ended September 30, 2025, a 67% reduction from $10.6 million in the same period of 2024.
• Cash and cash equivalents decreased to $7.5 million as of September 30, 2025, from $30.3 million at December 31, 2024.
• Accumulated deficit reached $229.3 million as of September 30, 2025.
• The company has initiated a strategic review to explore options like mergers, acquisitions, partnerships, or licensing to maximize stockholder value and secure funding.
• A workforce reduction of 21 out of 26 full-time employees was implemented in April 2025, with key executives transitioning to consulting roles in June 2025.
• Amezalpat, the lead program for first-line liver cancer (HCC), is poised to begin a pivotal Phase 3 study, having received positive FDA feedback and regulatory designations (Orphan Drug, Fast Track).
• TPST-1495, for Familial Adenomatous Polyposis (FAP), is expected to begin a Phase 2 study in late 2025, subject to potential delays from the U.S. government shutdown.
• The Oxford Loan of $3.5 million was fully repaid and terminated in April 2025.
• A Registered Direct Offering (RDO) in June 2025 raised approximately $4.1 million net.

Sentiment

Score: 3

Explanation: While there are significant positive clinical and regulatory developments for amezalpat and TPST-1495, the severe financial distress, explicit going concern warning, substantial cash burn, and the need for immediate strategic alternatives or wind-down of operations overshadow these positives. The workforce reduction and executive transitions further highlight the critical financial situation.

Positives

• Net loss significantly decreased by 67% for the three months ended September 30, 2025, to $3.5 million from $10.6 million in the prior year.
• Research and development expenses decreased by 92% to $0.6 million for the three months ended September 30, 2025, reflecting cost reduction efforts.
• Amezalpat, the lead product candidate, demonstrated positive survival data in a Phase 1b/2 study for first-line unresectable or metastatic HCC, showing a six-month improvement in median overall survival with a hazard ratio of 0.65.
• Amezalpat received positive feedback from the FDA on its pivotal Phase 3 clinical trial design and obtained a "Study May Proceed" letter from the FDA in November 2024, and "Clearance to Proceed" from China's NMPA in June 2025.
• Amezalpat was granted Orphan Drug Designation (ODD) by the FDA in January 2025 and the European Medical Agency (EMA) in June 2025 for HCC, providing potential regulatory benefits and market exclusivity.
• Amezalpat also received Fast Track Designation (FTD) from the FDA in February 2025, underscoring the urgent need for new HCC treatments.
• TPST-1495, for Familial Adenomatous Polyposis (FAP), received FDA Orphan Drug Designation in April 2025 and a "Study May Proceed" letter from the FDA for an NCI-funded Phase 2 clinical trial in March 2025.
• The company fully repaid and terminated its $3.5 million loan agreement with Oxford Finance LLC in April 2025, eliminating associated interest expense and liens.

Negatives

• The company has incurred operating losses since inception and reported an accumulated deficit of $229.3 million as of September 30, 2025.
• Cash and cash equivalents significantly decreased to $7.5 million as of September 30, 2025, from $30.3 million at December 31, 2024.
• Existing cash and cash equivalents are expected to fund operations for less than 12 months from the date the financial statements were issued, raising substantial doubt about the company's ability to continue as a going concern.
• A workforce reduction of 21 out of 26 full-time employees was implemented in April 2025, incurring $3.2 million in one-time cash severance payments and potentially leading to loss of institutional knowledge and decreased morale.
• Key executives, including the CEO, CMO, and CFO, transitioned to consulting arrangements in June 2025, which could impact leadership stability.
• The ATM Program prospectus supplement was suspended and terminated in June 2025, and the company is subject to "baby shelf rules" limiting future capital raises through this mechanism to one-third of its public float.
• The Phase 2 study for TPST-1495 is subject to potential delays resulting from the ongoing U.S. government shutdown.
• Interest income decreased by 73% for the three months ended September 30, 2025, to $86 thousand from $324 thousand in the prior year.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern, requiring significant additional funding that may not be available on acceptable terms or at all.
• Activities to evaluate strategic alternatives may not result in any transaction or enhance stockholder value, potentially leading to dissolution and liquidation.
• Raising additional capital may cause dilution to stockholders, restrict operations, or require relinquishing proprietary rights.
• The recently implemented corporate restructuring and workforce reduction may not yield expected benefits and could lead to loss of institutional knowledge, attrition, or decreased morale.
• A history of operating losses and anticipated future losses mean profitability may not be achieved or sustained.
• Inability to develop, obtain regulatory approval for, and commercialize product candidates (amezalpat, TPST-1495) or significant delays in doing so would materially harm the business.
• Success in preclinical studies and earlier clinical trials may not be indicative of results in later clinical trials, potentially delaying or preventing regulatory approval.
• The company may not be successful in expanding its pipeline of product candidates and developing marketable products.
• Commercial success depends on market acceptance by providers, patients, payors, and the medical community, which is uncertain.
• Reliance on third parties for manufacturing clinical product supplies and, if approved, commercial production, exposes the company to risks of supply disruption, quality issues, and compliance failures.
• Significant competition in the biopharmaceutical and immuno-oncology industries, with competitors potentially achieving regulatory approval faster or developing more effective therapies.
• Inability to establish sales and marketing capabilities or enter into third-party agreements could prevent revenue generation.
• The FDA regulatory approval process is lengthy, unpredictable, and subject to delays, potentially leading to narrower indications or post-marketing restrictions.
• Product candidates may cause undesirable side effects, leading to clinical trial suspension/termination, denial of approval, or market withdrawal.
• Interim and preliminary clinical data may change as more patient data becomes available and is subject to audit and verification.
• Investigating product candidates in combination with other therapies exposes the company to risks related to the approval, safety, efficacy, manufacturing, or supply of those combination therapies.
• Orphan Drug Designation does not guarantee market exclusivity or faster development/review, and exclusivity can be lost.
• Enacted and future legislation (e.g., ACA, IRA, OBBBA) may increase the difficulty and cost of commercialization, affect pricing, and impose new regulations.
• The FDA's ability to review and approve new products may be hindered by budget, funding, personnel, and policy changes, including government shutdowns.
• Stringent and evolving U.S. and foreign data privacy and security laws (e.g., CCPA, GDPR, OBBBA Rule on sensitive personal data) could lead to non-compliance penalties, litigation, and operational disruptions.
• Cyberattacks, data breaches, and other security incidents could compromise sensitive information, damage reputation, and lead to financial and legal exposure.
• Misconduct by employees, principal investigators, CROs, CMOs, and consultants, including non-compliance with regulatory standards and insider trading, could lead to penalties and reputational harm.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in others, and foreign regulatory requirements can be extensive and costly.
• Compliance with anti-kickback, fraud and abuse, and other healthcare laws and regulations is complex and non-compliance could lead to severe penalties.
• Failure to comply with environmental, health, and safety laws could result in fines or penalties.
• Changes in tax laws or regulations (e.g., OBBBA, IRA) could adversely affect the company.
• Challenges in obtaining, maintaining, and protecting intellectual property (patents, trade secrets) due to cost, complexity, legal challenges, and changes in patent law (e.g., America Invents Act, UPC).
• Reliance on in-licensed intellectual property and potential disputes with licensors.
• Risk of third-party claims of intellectual property infringement.
• Patent terms may be inadequate to protect competitive position.
• Intellectual property discovered through government-funded programs may be subject to "march-in" rights and U.S.-based manufacturing preferences.
• Volatility of common stock price due to clinical trial results, financial projections, regulatory actions, competition, and general market conditions.
• Reverse stock split may reduce market trading liquidity and potentially have an anti-takeover effect.
• Thinly traded common stock may lead to disproportionate price influence from small sales.
• As a smaller reporting company, reduced reporting requirements may make common stock less attractive to investors.
• Increased costs and management time required for public company compliance.
• Risk of delisting from Nasdaq.
• Adverse effects from natural disasters, public health crises, and other calamities.
• Significant product liability risk, with potential for insufficient insurance coverage.
• Anti-takeover provisions in corporate documents and Delaware law could make acquisitions more difficult.
• No anticipated cash dividends in the foreseeable future.
• Lack of equity research analyst coverage could impact stock price and trading volume.

Future Outlook

The company is actively exploring strategic alternatives, including mergers, acquisitions, partnerships, or licensing, to advance its clinical-stage programs and maximize stockholder value. Amezalpat is poised to begin a pivotal Phase 3 study in first-line HCC, subject to securing additional financial resources. TPST-1495 is expected to start a Phase 2 study in FAP in late 2025, though this is subject to potential delays from the U.S. government shutdown. The company anticipates continued operating losses for the foreseeable future and will require additional financing to achieve its business objectives.

Management Comments

• "We announced plans to explore a full range of strategic alternatives to advance our promising clinical stage programs and maximize stockholder value."
• "If a strategic alternative is not available to us, we will be required to take additional actions to fund the Company's operations or we may be forced to wind down our operations."
• "We expect that our existing cash and cash equivalents will fund our projected operating expense requirements through less than 12 months from the date our consolidated financial statements were available to be issued."
• "We believe the continued positive results from the ongoing randomized Phase 1b/2 study provides strategic opportunities for us, and we received positive feedback from the FDA and European Medicines Agency (EMA) on the pivotal Phase 3 clinical trial design."

Industry Context

Tempest Therapeutics operates in the highly competitive and rapidly changing biopharmaceutical and immuno-oncology industry. The company's focus on novel, first-in-class treatments for various cancers, particularly amezalpat for HCC and TPST-1495 for FAP, positions it in areas with significant unmet medical needs. The positive regulatory designations (Orphan Drug, Fast Track) for amezalpat and TPST-1495 highlight the potential importance of these candidates within their respective therapeutic areas. However, the industry is characterized by intense competition from larger, well-funded companies, and the high costs and risks associated with clinical development and regulatory approval. The company's current financial distress and reliance on strategic alternatives reflect broader market conditions and funding challenges often faced by clinical-stage biotech firms.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.
• The positive Phase 1b/2 survival data for amezalpat in HCC, showing a six-month improvement in median overall survival with a hazard ratio of 0.65, is a strong indicator of potential efficacy in a challenging cancer indication. This type of survival benefit, if replicated in Phase 3, would be considered significant in oncology drug development.
• The receipt of Orphan Drug and Fast Track designations from the FDA and EMA for both lead candidates suggests recognition of their potential to address unmet needs, which is a positive signal within the industry.
• The company's financial position, however, with a going concern warning and significant cash burn, is below industry standards for sustainable operations without further capital.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings that, if determined adversely, would have a material adverse effect on the business, financial position, results of operations, or cash flows.

Related Party Transactions

• Success bonus agreements totaling $725,000 were entered into on August 11, 2025, with certain individuals, including Stephen Brady (CEO), Samuel Whiting (CMO), Nicholas Maestas (CFO), and Justin Trojanowski (Corporate Controller), contingent on a change in control prior to January 31, 2026.

Stakeholder Impact

• Shareholders: Face substantial dilution risk from future capital raises, potential loss of investment if strategic alternatives fail and the company winds down, and volatility in stock price. The reverse stock split may reduce liquidity.
• Employees: Significant workforce reduction (21 of 26 full-time employees) has occurred, leading to job losses and potential impact on morale for remaining staff. Key executives transitioned to consulting roles.
• Customers/Patients: Potential for new cancer treatments (amezalpat for HCC, TPST-1495 for FAP) if development is successful, but ongoing financial uncertainty could delay or halt these programs.
• Creditors: The Oxford Loan has been fully repaid, reducing immediate debt obligations. However, the going concern warning indicates elevated risk for future creditors.
• Suppliers/Partners: Reliance on third-party CROs and CMOs means their operations could be impacted by the company's financial instability or strategic shifts.

Next Steps

• Continue exploring strategic alternatives (mergers, acquisitions, partnerships, joint ventures, licensing, or other strategic transactions) to maximize stockholder value.
• Seek additional funding to finance operations.
• Advance amezalpat into a pivotal Phase 3 study in first-line HCC patients, subject to securing additional financial resources.
• Initiate a Phase 2 study for TPST-1495 in patients with FAP with the CP-CTNet, expected in late 2025 (subject to potential delays).
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on condensed consolidated financial statements and annual estimated effective tax rate.
• Potentially file a new prospectus, prospectus supplement, or registration statement to resume sales under the ATM Program, if public float conditions allow.

Key Dates

Recommendation

Despite promising clinical data and regulatory designations for amezalpat and TPST-1495, the company faces an immediate and severe liquidity crisis, explicitly stating "substantial doubt about the Company's ability to continue to operate as a going concern." The significant cash burn, drastic workforce reduction, and executive transitions underscore the critical financial instability. While a strategic review is underway, there is no guarantee of a successful outcome, and the potential for dissolution and liquidation is explicitly mentioned. The "baby shelf rules" further limit immediate capital raising options. The high risk of total loss of investment, coupled with the urgent need for external funding, makes the stock a strong sell for investors.

Keywords

Tempest Therapeutics, TPST, 10-Q, Biotechnology, Oncology, Cancer Treatment, Amezalpat, TPST-1120, Hepatocellular Carcinoma, HCC, Phase 3 Clinical Trial, Orphan Drug Designation, Fast Track Designation, TPST-1495, Familial Adenomatous Polyposis, FAP, Phase 2 Clinical Trial, Going Concern, Strategic Alternatives, Workforce Reduction, SEC Filing, Financial Results, Clinical Stage, Drug Development, PPAR antagonist, EP2/EP4 antagonist